These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29929757)

  • 1. A clinical prediction model to estimate the metastatic potential of pheochromocytoma/paraganglioma: ASES score.
    Cho YY; Kwak MK; Lee SE; Ahn SH; Kim H; Suh S; Kim BJ; Song KH; Koh JM; Kim JH; Lee SH
    Surgery; 2018 Sep; 164(3):511-517. PubMed ID: 29929757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative prediction of metastatic pheochromocytoma and paraganglioma using clinical, genetic, and biochemical markers: A cohort study.
    Park SS; Ahn CH; Lee S; Lee W; Kim WW; Lee YM; Kim SJ; Sung TY; Lee KE; Kim JH; Lee SH; Koh JM
    J Intern Med; 2024 Jul; 296(1):68-79. PubMed ID: 38659304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation and Evaluation of 5 Scoring Systems for Predicting Metastatic Risk in Pheochromocytoma and Paraganglioma.
    Li Q; Lan Z; Jiang Y; Wang R; Li Z; Jiang X
    Am J Surg Pathol; 2024 Jul; 48(7):855-865. PubMed ID: 38712603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma.
    Koh JM; Ahn SH; Kim H; Kim BJ; Sung TY; Kim YH; Hong SJ; Song DE; Lee SH
    PLoS One; 2017; 12(11):e0187398. PubMed ID: 29117221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems.
    Wachtel H; Hutchens T; Baraban E; Schwartz LE; Montone K; Baloch Z; LiVolsi V; Krumeich L; Fraker DL; Nathanson KL; Cohen DL; Fishbein L
    J Clin Endocrinol Metab; 2020 Dec; 105(12):e4661-70. PubMed ID: 32877928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma.
    Assadipour Y; Sadowski SM; Alimchandani M; Quezado M; Steinberg SM; Nilubol N; Patel D; Prodanov T; Pacak K; Kebebew E
    Surgery; 2017 Jan; 161(1):230-239. PubMed ID: 27839933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lesion-based indicators predict long-term outcomes of pheochromocytoma and paraganglioma- SIZEPASS.
    Hanschell H; Diaz-Cano S; Blanes A; Talat N; Galatá G; Aylwin S; Schulte KM
    Front Endocrinol (Lausanne); 2023; 14():1235243. PubMed ID: 37600698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years.
    Hamidi O; Young WF; Iñiguez-Ariza NM; Kittah NE; Gruber L; Bancos C; Tamhane S; Bancos I
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3296-3305. PubMed ID: 28605453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma.
    Roman-Gonzalez A; Zhou S; Ayala-Ramirez M; Shen C; Waguespack SG; Habra MA; Karam JA; Perrier N; Wood CG; Jimenez C
    Ann Surg; 2018 Jul; 268(1):172-178. PubMed ID: 28257320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.
    Ayala-Ramirez M; Feng L; Johnson MM; Ejaz S; Habra MA; Rich T; Busaidy N; Cote GJ; Perrier N; Phan A; Patel S; Waguespack S; Jimenez C
    J Clin Endocrinol Metab; 2011 Mar; 96(3):717-25. PubMed ID: 21190975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical course and prognostic factors in patients with malignant pheochromocytoma and paraganglioma: A single institution experience.
    Choi YM; Sung TY; Kim WG; Lee JJ; Ryu JS; Kim TY; Kim WB; Hong SJ; Song DE; Shong YK
    J Surg Oncol; 2015 Dec; 112(8):815-21. PubMed ID: 26464058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas.
    Pierre C; Agopiantz M; Brunaud L; Battaglia-Hsu SF; Max A; Pouget C; Nomine C; Lomazzi S; Vignaud JM; Weryha G; Oussalah A; Gauchotte G; Busby-Venner H
    Virchows Arch; 2019 Jun; 474(6):721-734. PubMed ID: 30868297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regarding: A clinical prediction model to estimate the metastatic potential of pheochromocytoma/paraganglioma: ASES score.
    Mattoo S; Agarwal A; Mayilvaganan S; Agarwal G; Mishra A; Mishra SK; Chand G
    Surgery; 2019 Apr; 165(4):853-858. PubMed ID: 30409407
    [No Abstract]   [Full Text] [Related]  

  • 14. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma.
    Kimura N; Takayanagi R; Takizawa N; Itagaki E; Katabami T; Kakoi N; Rakugi H; Ikeda Y; Tanabe A; Nigawara T; Ito S; Kimura I; Naruse M;
    Endocr Relat Cancer; 2014 Jun; 21(3):405-14. PubMed ID: 24521857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Catecholamine-Synthesizing Enzymes in Pheochromocytoma and Extraadrenal Paraganglioma.
    Konosu-Fukaya S; Omata K; Tezuka Y; Ono Y; Aoyama Y; Satoh F; Fujishima F; Sasano H; Nakamura Y
    Endocr Pathol; 2018 Dec; 29(4):302-309. PubMed ID: 30155766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reply to letter to editor regarding: "A clinical prediction model to estimate the metastatic potential of Pheochromocytoma/paraganglioma: ASES score".
    Cho YY; Kwak MK; Lee SE; Kim JH; Lee SH
    Surgery; 2019 Apr; 165(4):853-858. PubMed ID: 30686514
    [No Abstract]   [Full Text] [Related]  

  • 17. Morphological and immunohistochemical characteristics associated with metastatic and recurrent progression in pheochromocytoma/paraganglioma: A cohort study.
    Wang LL; Wei XJ; Zhang QC; Li F
    Ann Diagn Pathol; 2022 Oct; 60():151981. PubMed ID: 35660808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of metastatic pheochromocytoma and paraganglioma: a machine learning modelling study using data from a cross-sectional cohort.
    Pamporaki C; Berends AMA; Filippatos A; Prodanov T; Meuter L; Prejbisz A; Beuschlein F; Fassnacht M; Timmers HJLM; Nölting S; Abhyankar K; Constantinescu G; Kunath C; de Haas RJ; Wang K; Remde H; Bornstein SR; Januszewicz A; Robledo M; Lenders JWM; Kerstens MN; Pacak K; Eisenhofer G
    Lancet Digit Health; 2023 Sep; 5(9):e551-e559. PubMed ID: 37474439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic pheochromocytoma: does the size and age matter?
    Zelinka T; Musil Z; Dušková J; Burton D; Merino MJ; Milosevic D; Widimský J; Pacak K
    Eur J Clin Invest; 2011 Oct; 41(10):1121-8. PubMed ID: 21692797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma.
    Pamporaki C; Prodanov T; Meuter L; Berends AMA; Bechmann N; Constantinescu G; Beuschlein F; Remde H; Januszewicz A; Kerstens MN; Timmers HJLM; Taïeb D; Robledo M; Lenders JWM; Pacak K; Eisenhofer G
    Eur J Cancer; 2022 Jul; 169():32-41. PubMed ID: 35500459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.